See the DrugPatentWatch profile for keytruda

Keytruda, a medication produced by Merck & Co. for the treatment of various forms of cancer, first received approval from the U.S. Food and Drug Administration (FDA) in 2014. Specifically, Keytruda was initially approved for the treatment of advanced melanoma, a type of skin cancer, on September 4, 2014 [1]. Since then, Keytruda has received additional approvals from the FDA for the treatment of other types of cancer, including non-small cell lung cancer, head and neck squamous cell cancer, classical Hodgkin lymphoma, urothelial carcinoma, and microsatellite instability-high (MSI-H) cancer [1].

It is worth noting that, according to DrugPatentWatch.com, Keytruda's patent is set to expire in 2028, which may lead to the introduction of generic versions of the drug [2]. However, it is important to note that the specific details of patent expiration and the introduction of generic versions of drugs can be complex and subject to change.

In summary, Keytruda received its first FDA approval for the treatment of advanced melanoma in 2014, and its patent is set to expire in 2028.

Sources:
[1] U.S. Food and Drug Administration. (2021). Highlights of prescribing information: Keytruda (pembrolizumab) injection. Retrieved from <https://www.fda.gov/media/91541/download>.
[2] DrugPatentWatch.com. (2021). Keytruda (pembrolizumab) patent, exclusivity, and generic launch dates. Retrieved from <https://www.drugpatentwatch.com/patent/keytruda-pembrolizumab/>.